Audentes Therapeutics to Present at Upcoming Investor Conferences

SAN FRANCISCO, Feb. 7, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences:

• LEERINK Partners 6th Annual Global Healthcare ConferenceFebruary 15, 2017, 9:00 am ETLotte New York Palace, New York, NY
• Cowen and Company 37th Annual Health Care ConferenceMarch 7, 2017, 9:20 am ETBoston Marriott Copley Place, Boston, MA

To access a live webcast of the presentations, please visit the Events & Presentations page within the Investors & News section of the Audentes website.  Replays of live webcasts will be available on the Audentes website for approximately 30 days following the conferences.

About Audentes Therapeutics, Inc.

Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.  We have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit www.audentestx.com.

Audentes Contacts:

Investor Contact:Thomas Soloway, CFO415.818.1040[email protected]

Media Contact:Jeffrey Gruis415.818.1015[email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-present-at-upcoming-investor-conferences-300402310.html

SOURCE Audentes Therapeutics, Inc.